Drug intelligence / Profile preview

prefusion F

Development stage: Unknown
Lead developer: AstraZeneca
Modality: Vaccines & Immunotherapeutics
Administration: Intramuscular

Overview

Prefusion F is a prefusion antigen for human metapneumovirus (hMPV) that incorporates key mutations to stabilize the viral fusion (F) protein in its prefusion conformation. This antigen was licensed by Icosavax from the National Institutes of Health (NIH) and the University of Texas at Austin. It serves as a critical component of Icosavax's (now AstraZeneca's) bivalent virus-like particle (VLP) vaccine candidate, IVX-A12, which targets both hMPV and Respiratory Syncytial Virus (RSV).

Targets

HMPV F (Human metapneumovirus fusion protein)

Beyond the preview

Go deeper on prefusion F.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on prefusion F.

Explore the full profile